Profile for Brazil Patent: 112015005894

US Patent Family Members and Approved Drugs for Brazil Patent: 112015005894

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
11,666,566	Mar 18, 2034	Teva Branded Pharm	AUSTEDO	deutetrabenazine
9,233,959	Mar 18, 2034	Teva Branded Pharm	AUSTEDO	deutetrabenazine
9,296,739	Mar 18, 2034	Teva Branded Pharm	AUSTEDO	deutetrabenazine

Key insights for pharmaceutical patentability - Brazil patent BR112015005894

Last updated: April 26, 2026

Brazil Patent BR112015005894: Claim Scope, Legal Position, and Landscape Impact

BR112015005894 is a Brazilian patent publication with claims that define a narrow set of protected subject matter tied to the specific formulation and/or therapeutic use recited in the document. Without the underlying publication text (claims, description, and prosecution status), a complete and accurate mapping of (i) claim elements, (ii) dependent-claim fallbacks, (iii) claim construction boundaries, (iv) enforceable scope in Brazil, and (v) the surrounding freedom-to-operate and generic/biosimilar landscape cannot be produced.

Because the requested deliverable requires exact claim-language analysis and landscape linkage to the precise patent family and claim set, no response is provided.

Key Takeaways

• No verifiable analysis of claim scope or patent landscape can be completed for BR112015005894 without the patent’s full text (claims and legal status).
• Any attempt to summarize scope without the actual claim language risks producing incorrect legal boundaries, which is not acceptable for decision-grade patent work.

FAQs

1. What does “scope and claims analysis” include for a Brazilian patent?
   It maps each independent and dependent claim into technical elements, identifies limitations that drive infringement/non-infringement, and links claim structure to likely validity and design-around risks.

2. What drives whether a generic can enter in Brazil against a specific patent?
   The claim set, enforcement status (granted or under examination), and whether any regulatory pathway triggers patent linkage or enforcement.

3. How is a “patent landscape” usually built for a single Brazil application?
   It links the application to its international family members, earlier priority filings, prosecution outcomes, and neighboring patents that cover the same compound, formulation, method of use, or process.

4. Why does prosecution status matter for infringement risk?
   Pending claims can change; granted claims lock scope. Enforcement and effective filing dates determine whether other developments fall inside or outside protection.

5. What artifacts are required for claim construction-quality analysis?
   The published application text including claim set, description support for claim terms, and the publication/grant/legal status in Brazil.